Literature DB >> 20139941

The HER2 testing conundrum.

Malorye Allison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20139941     DOI： 10.1038/nbt0210-117

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Authors:  Kathryn A Phillips; Deborah A Marshall; Jennifer S Haas; Elena B Elkin; Su-Ying Liang; Michael J Hassett; Ilia Ferrusi; Jane E Brock; Stephanie L Van Bebber
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

2.  Trastuzumab: a picky partner?

Authors:  Heather L McArthur; Clifford A Hudis
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531
  2 in total
  34 in total

1.  Primary trastuzumab resistance: new tricks for an old drug.

Authors:  Jason A Wilken; Nita J Maihle
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

2.  Reinventing clinical trials.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

3.  US pharmacies broaden access to pharmacogenetic tests.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-04       Impact factor: 54.908

4.  Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells.

Authors:  Benjamin Thierry; Mahaveer Kurkuri; Jun Yan Shi; Lwin Ei Mon Phyo Lwin; Dennis Palms
Journal:  Biomicrofluidics       Date:  2010-09-30       Impact factor: 2.800

5.  Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.

Authors:  Carlos Gómez-Martín; Angel Concha; José María Corominas; Tomás García-Caballero; Elena García-García; Mar Iglesias; José Antonio López; Santiago Ramón y Cajal; Federico Rojo; José Palacios; Francisco Vera-Sempere; Enrique Aranda; Ramon Colomer; Pilar García-Alfonso; Pilar Garrido; Fernando Rivera; Fernando López-Ríos
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

6.  68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.

Authors:  Gabriela Kramer-Marek; Nalini Shenoy; Jurgen Seidel; Gary L Griffiths; Peter Choyke; Jacek Capala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

7.  The epidermal growth factor receptor conundrum.

Authors:  Jason A Wilken; Andre T Baron; Nita J Maihle
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

Review 8.  Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Authors:  Jingjuan Qiao; Shenghui Xue; Fan Pu; Natalie White; Jie Jiang; Zhi-Ren Liu; Jenny J Yang
Journal:  J Biol Inorg Chem       Date:  2013-12-24       Impact factor: 3.358

Review 9.  Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

Authors:  Shenghui Xue; Jingjuan Qiao; Fan Pu; Mathew Cameron; Jenny J Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-01-17

10.  Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.

Authors:  Marta Kijanka; Frank-Jan Warnders; Mohamed El Khattabi; Marjolijn Lub-de Hooge; Gooitzen M van Dam; Vasilis Ntziachristos; Liesbeth de Vries; Sabrina Oliveira; Paul M P van Bergen En Henegouwen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-19       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.